U.S. President Donald Trump signed an executive order on Thursday imposing 100% tariffs on branded pharmaceuticals imported into the U.S. unless manufacturers agree to government drug pricing deals or commit to making their products domestically. The move is intended to push drugmakers to onshore production and cut U.S. prescription drug prices.
Core Facts and Immediate Action
The 100% tariff applies to patented drugs not made in the U.S. and not covered by drug pricing agreements. Large pharmaceutical companies have 120 days to announce plans to avoid the tariff, while smaller companies have 180 days. Companies can move manufacturing to the U.S. in exchange for a reduced 20% tariff. Drugmakers that onshore and sign most-favored-nation pricing agreements with the U.S. Department of Health and Human Services are exempt from tariffs.
Deeper Dive and Context
Existing Agreements and Exemptions
The U.S. has already agreed to such deals with 17 drugmakers, of which 13 have been finalized and four are being negotiated. Tariffs are reduced to 15% for drugs produced in the European Union, Japan, South Korea, and Switzerland due to existing trade agreements. The U.K. has a separate tariff deal. Generic drugs will be exempt from tariffs for at least one year.
Impact on Pharmaceutical Industry
Major drugmakers that have signed deals, which exempt them from tariffs for three years, include Pfizer and Eli Lilly. Many companies, including about half of those represented by industry lobby group PhRMA, have not yet signed deals. Industry sources say small and mid-sized drugmakers are seeking individual arrangements to avoid tariffs and new pricing agreements.
Global Implications
Pharmaceuticals are among Australia's top exports to the U.S., worth about $1.3 billion last year. Melbourne-based manufacturer CSL has been investing in U.S. manufacturing to circumvent the tariff. The U.S. argues domestic pharmaceutical production is necessary to ensure a secure supply of vital drugs.
Political and Economic Context
The tariff is being implemented under a section of trade law designed to protect national security, which means it is unaffected by the Supreme Court decision that invalidated Trump's centerpiece 'liberation day' tariffs. The move reflects anger inside the administration about international pricing systems, including Australia's Pharmaceutical Benefits Scheme, which mean Americans often pay much higher prices for medicines than overseas customers.
Diverse Perspectives
Some sources highlight the potential for the tariff to drive domestic production and lower drug prices for U.S. consumers. Others emphasize the burden on small and mid-sized drugmakers, who may struggle to meet the new requirements. The tariff also raises questions about the impact on global trade relations and the pharmaceutical supply chain.